P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials

Similar Items

• P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
  by: Andrea Doria, et al.
  Published: (2024-03-01)
• O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
  by: Andrea Doria, et al.
  Published: (2024-03-01)
• 22 New and approved therapies for SLE: Anifrolumab
  by: Ronald van Vollenhoven
  Published: (2022-04-01)
• 06 Approved biologics for SLE: which to try first and in which patients? – The case for anifrolumab
  by: Eric Morand
  Published: (2023-09-01)
• P133 Anifrolumab treatment improves quality of life and decreases corticosteroid use in patients with SLE
  by: Anne Troldborg, et al.
  Published: (2024-03-01)